Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Raised by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 35.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 851 shares of the biopharmaceutical company’s stock after purchasing an additional 223 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $747,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Meyer Handelman Co. increased its position in shares of Regeneron Pharmaceuticals by 11.4% in the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after purchasing an additional 435 shares during the last quarter. Stifel Financial Corp grew its position in shares of Regeneron Pharmaceuticals by 12.2% during the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after buying an additional 3,385 shares during the last quarter. LPL Financial LLC grew its position in shares of Regeneron Pharmaceuticals by 9.3% during the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after buying an additional 3,479 shares during the last quarter. Cavalier Investments LLC grew its position in shares of Regeneron Pharmaceuticals by 88.6% during the 3rd quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company’s stock valued at $3,651,000 after buying an additional 2,084 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its position in shares of Regeneron Pharmaceuticals by 32.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after buying an additional 1,221 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Marion Mccourt sold 358 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $967.50, for a total value of $346,365.00. Following the sale, the executive vice president now directly owns 13,431 shares in the company, valued at approximately $12,994,492.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock worth $13,124,641 in the last ninety days. 8.83% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ:REGN opened at $943.89 on Wednesday. The company has a 50 day moving average of $959.25 and a 200-day moving average of $887.65. The firm has a market cap of $103.60 billion, a P/E ratio of 27.16, a P/E/G ratio of 2.74 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the prior year, the business posted $10.96 EPS. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on REGN. Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 5th. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective for the company. Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the company a “neutral” rating in a research note on Tuesday, February 6th. Finally, Truist Financial reissued a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $968.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.